EGFR and non-small cell lung carcinoma: Long's study revealed that continuous original TKI combined with bevacizumab showed partly favorable efficacy with 8 months of PFS2 and safety in EGFR‐mutant NSCLC patients experiencing gradual progression after EGFR‐TKI treatment [23].